

Analysis of Biosimilars Policies: The European, American, and Canadian Landscape

Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines June 28, 2022





Introduction

Michael Reilly, ESQ Executive Director, Alliance for Safe Biologic Medicines 2010-Present


- Associate Deputy Secretary at the U.S. Department of Health and Human Services (HHS) from 2005-2008
- Responsible for policy development and implementation, regulatory oversight for issues involving CMS and the FDA.
- Senior Advisor to the Assistant Secretary for Public Affairs and the Assistant Secretary for Planning and Evaluation at HHS from 2002-2005

Biosimilars Working Group


ASBM is also a member of the Canadian Biosimilars Working Group:

Alliance for Safe Biologic Medicines Canadian Council of the Blind Canadian Organization for Rare Disorders Canadian Society of Intestinal Research Crohn's and Colitis Canada Gastrointestinal Society HS (hidradenitis suppurativa) Heroes International Federation on Ageing MedAccess BC

biosimilaroptions.ca



Joint PMPRB Comments: February 14, 2020




June 29 Webinar: "Key Factors for Successful Uptake of Biosimilars: Europe and US"

- Tomorrow ASBM & GaBI will present a webinar which discusses the factors contributing to the success of biosimilars in Europe and the U.S.
- This is the first in a series of webinars presented by ASBM and GaBI this year.



REGISTER



Non-Medical Switching Webinar: July 20th

Non-Medical Switching is a concern we have seen across our surveys and among patients.

Our next webinar (July 20th) will delve more deeply into physician concerns with non-medical switching and forced substitution- as well as discussing how the FDA designation of a biosimilar as "Interchangeable" shows promise as an effective means of addressing these lingering concerns for most physicians.



Europe Enjoys High Biosimilar Uptake Rates and Savings

Biosimilar Uptake Varies Throughout Europe by Country and Product (Usually 20-80% range):

<u>Total Biosimilar Volume</u>: Denmark: 63%; UK: 45%; Germany 40%; France 34%, Belgium and Switzerland tied at 14%.

Filgrastim/Pegfilgrastim: 16 European countries had> 90% biosimilar utilization in 2018, Ireland was just 27%.

<u>Anti-TNF biosimilars</u> (adalimumab, etanercept and infliximab): Norway and Denmark had 81% and 96% biosimilar uptake, respectively, while every other country's utilization was less than 50%.



Variations are influenced by government involvement, reimbursement structures and tender procurement policies.

Biosimilar Policy in Europe: A Collaborative, Patient-Focused Approach

- Regular multi-stakeholder consultations held by European Commission in Brussels.
- Discussions about switching are made collaboratively between health care providers and patients.
- Education of patients to build trust in biosimilars has been a priority.
- Savings attributed to biosimilars are being visibly reinvested into the systemmore healthcare workers, etc.




Survey Presented at ESMO Congress 2019

- An update of a prior survey in 2013
- The survey findings were presented at the European Society of Medical Oncology 2019 Congress in Barcelona, Spain.
- The European physicians took great pride in their approach, which is very patient-focused.
- Notably, as familiarity and comfort with biosimilars increased, <u>so did the importance to</u> <u>physicians of maintaining control of treatment</u> <u>decision.</u>



Michael Reilly, Esg, ¹ and Andrew Spiegel, Esg ²				
¹ Alliance for Safe Biologic Medicines, Arlington, VA, USA; ² Global Colon Cancer Association, Bala Cynwyd, PA, USA				
BACKGROUND	RESULTS	Prescribing Biosimilars: Treatment-Naïve vs. Stable Patients	National Tenders From your perspective, how important is it for government tenders	
Biosimilars are highly similar, but not identical to originator	Responses	"How comfortable are you in prescribing a biosimilar to a	for biasimilars to be awarded to multiple suppliers? (n=579)	
biologics. In an increasingly resource-constrained environment, switching	A total of 579 responses were received:	treatment 'naive' patient?"	Most respondents (63%) feel that it is either "Very Important" or	
patients from originator biologics to biosimilars is a growing	 France: 97 (17%) Spain: 96 (17%) 	"How comfortable are you with switching a stable patient from one medicine to a biosimilar?"	"Critical" for tenders to be awarded to multiple suppliers.	
practice in many jurisdictions.	 Germany: 97 (17%) Switzerland: 95 (17%) 	A strong majority (84%) of physicians are comfortable	inwarding Kational Earders in Multiple Suppliers	
Though automatic substitution of originator biologics with biosimilars is rare in Europe, this practice excludes physicians	* kaly: 97 (17%) * United Kingdom: 97 (17%)	prescribing biosimilars to treatment naive patients. Comfort	1004	
from decisions regarding the treatment of their patients.	 The largest group of prescribers (47%) practice in a hospital setting, with the remainder in academic medical centers (23%) 	level decreases to 80% when asked about switching a stable referr to a biosimilar	Way insertion	
The Atlance for Safe Biologic Medicines (ASBM) commissioned 15-minute web-based surveys among biologic prescribers in	private/family practice (18%), multi-specialty clinics (8%),	While 17% are uncomfortable in prescribing a biosimilar to a	Sonewhat Ingestant	
6 Western European countries to empirically document their	community settings (3%) and other settings (1%). * Respondents' mean experience level was 15.5 years in practice.	naïve patient; more than twice as many (40%) are	Signity ingenance 66	
perspectives on biologic substitution.	 Respondence mean experience reverses to 5 years in process. The percentage of physicians who rate themselves as being 	uncomfortable with switching a stable patient to a biosimilar	Not inquirante and 16	
This survey is a refresh of one conducted in 2013 (n=470). Both may be found at: www.safebiologics.org/surveys	"familiar" or "very familiar" with biosimilars has increased from	Procide Residents to Restrict Nation Parliet		
As countries seek to control health costs and expand access to	76% in 2013 to 90% in 2019.		"From your perspective, how important is it for factors besides price to be taken into account in national tender offers (c.a. reliability of supply.	
biologic therapies, building physician confidence in biosimilars is critical to promoting their use and reaping the cost benefits.	Treatment Decision Authority	anderstee Int contraste	patient support services, manufacturer reputation?" (n=579)	
These findings may serve as a resource for countries in	"How important is it to you to have the sole authority to	Invested you, Mittania and	A strong majority of respondents (83%) feel that it is either "Very	
developing biosimilar policies which build physician confidence	decide, together with your patients, the most suitable	0000000 0000000	Important' or "Critical" for national tender offers to consider factors besides price.	
in biosimilars.	biologic medicine for their disease?" (n=579)	Invested 114 Souther EX	National funders considering factors husides Price	
ETHODS	A strong majority of respondents (82%) feel that it is either "Very Important" or "Critical" for them to decide which biologic medicine		Drived 10%	
	is dispensed to their patients, an increase (from 72%) in the 2013	uncontention 26 W19 and 26	Veg Inpursed	
igibility Criteria	burvey.		Somewhat Imperson	
Must prescribe biologic medicines in their practice	Nole Ref Netly in Double Seattheast (2003) July Authority to Oscille Tendeneri (2028)		Sight insuran III N	
Vust practice in France, Germany, Italy, Spain, Switzerland, or United Kingdom.	Citical Sea	Non-Medical Switching	No marched and	
Must specialize in one of 10 practice areas: Dermatology.	ingenere Alla wysepotat	"How comfortable are you with switching your patient to a biosimilar for non-medical reasons (i.e., cost)?" (n=579)		
Endocrinology, Gastroenterology, Hematology Oncology,	Sonawhet 22% Sonawhet 14%	"How comfortable are you with a third party switching	CONCLUSIONS	
mmunology, Nephrology, Neurology, Oncology, Ophthalmology, Rheumatology	Hanny and An Hanny In-	your patient to a biosimilar for non-medical reasons (i.e.,		
	NY IN Detroyets IN	cost)?" (n=579)	 Our survey reveals that European physicians have increased their familiarity with biosimilars since last surveyed in 2013. After 	
dine Surveys		More than half of prescribers (58%) are uncomfortable with switching their patients to a biosimilar for non-medical	13 years of experience with biosimilars in Europe, physicians:	
rveys were administered in March 2019 by Industry Standard	Authority to Prevent a Substitution	reasons.	 Increasingly consider maintaining physician control of treatment decisions to be highly important 	
esearch, LLC. Prescribers were asked to rate:	'In a situation where substitution by a pharmacist was an	This percentage increases to 73% when asked about a third party initiating such a switch.	* Are more than twice as uncomfortable switching a stable patient	
 The importance of retaining sole authority to decide the most suitable biologic for their patients. 	option in your country, how important would it be to you to have the authority to designate a biologic medicine as	band meaning ages a service	to a biosimilar than they are prescribing a biosimilar to a treatment naïve patient.	
2. The importance of retaining the authority to deny/prevent a	'DISPENSE AS WRITTEN' or 'DO NOT SUBSTITUTE'?" (n=579)	Physics and Part Medical Section in Restories	* Remain uncomfortable with switching a patient to a biosimilar for	
substitution by indicating "Do Not Substitute" or similar anguage when prescribing.	A strong majority of respondents (84%) consider authority to prevent a substitution either "Very Important" or "Critical", an	Has head of the Party	non-medical reasons.	
anguage when prescribing. 3. Their comfort level with a) prescribing a biosimilar to a new	increase (from 74%) in the 2013 survey.	Wy contribution III Wy contribution III 76	 Are highly uncomfortable with a non-medical substitution performed by a third party. This figure has increased sharply 	
(treatment naïve) patient; and b.) switching a stable patient	Authority to Persent a Salestination (2013) Authority to Persent a Salestination (2013)		since the 2013 survey	
from an originator biologic to a biceimiter.	Diad 276. CRUI MR.	anderdare RN Scherer 200	 Consider it highly important for governments to make multiple theraneutic choices available in teoriers, and before these 	
 Their comfort level with a biosimilar switch for non-medical reasons (e.g., cost, coverage) a) when performed by the 	Wy martine Wy my market IR.	Invested IN Invester IN	tenders should take into account factors besides price.	
physician and b) when performed by a third party.	Schueld Internation	PERSONAL PROPERTY AND A DESCRIPTION OF A		
5. The importance of awarding government tenders on	Ngalar Ngalar Ngalar	unconfinition 20% Way ancient of the Decision 20%	DISCLOSURE	
originator biologics and biosimilars to multiple suppliers.	NO INCOME IN INCOME IN		ASBM is a group of physicians, pharmacists, patients, researchers, manufacturers, and others working together to promote the safe	
 The importance of national tender offers including factors besides price. 	An approximation of the		introduction and use of biosimilars. This survey was funded by ASBI	

European Surveys (2013 vs. 2019): Importance of Physician/Patient Control of Treatment Decisions



82% feel that it is either "Very Important" or "Critical" for the physician & patient to decide which biologic medicine is used, an increase (from 72%) since 2013. Those considering this "Critical" nearly doubled from 24% to 40%.

"Policy Recommendations for a Sustainable Biosimilars Market: Lessons from Europe"


- Generics and Biosimilars Initiative Journal (GaBI Journal). Published in: Volume 9 / Year 2020 / Issue 2
- Authors: Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
- Analyzed the different approaches to biosimilar policy across Europe
- **OBJECTIVE:** identify principles which can be applied to develop an efficient and sustainable biosimilar market.



Biosimilars markets: US and EU

The European Whitepaper Identified "Must-Have" Principles, Critical for Countries to Achieve Biosimilar Success:

 Physicians should have the <u>freedom to choose</u> <u>between off-patent originator biologicals and</u> <u>available biosimilars</u> and to act in the best interest of their patients based on scientific evidence and clinical experience.



3. A <u>level playing field</u> between all participating manufacturers is the best way to foster competition; mandatory discounts which place artificial downward pressure on manufacturers do not engender a sustainable market environment.

Outliers: Norway and Denmark

- Even in Norway with a national tendering system, physicians retain the prescription choice among all available products but are strongly encouraged to choose the lowest priced product for new patients.
- Only Denmark, following a transparent process, will solely reimburse the winning product, except in rare substantiated circumstances.



 Critically: No European country has stopped reimbursement of an originator product through an arbitrary government fiat as occurs in the Alberta and British Columbia forced-switching policies.

While Europe is Viewed as the Leader in Biosimilar Adoption, the U.S. is Catching Up...

- U.S. biosimilar market shares are catching up with European uptake rates:
- 80% for filgrastim biosimilars, 70% for trastuzumab and bevacizumab biosimilars, and 55% for rituximab biosimilars.
- Infliximab biosimilars have had the most • limited adoption, with approximately 20% market share.



And Then, There's Canada...



Canadian Proponents of Forced-Switching Often Cite European Experience to Justify These Policies...



British Columbia, May 2019

"British Columbia (B.C.) is following evidence-based results from a number of international jurisdictions that have over 10 years' experience with these innovative drugs."

"B.C. is leading the country by promoting the widespread use of biosimilars, which have been proven to work just as safely and effectively as higher priced biologics. To date, Canada is far behind European jurisdictions."

-Adrian Dix, Minister of Health, May 17, 2019



Alberta, December 2019

Health Minister Tyler Shandro cited European biosimilars experience to defend his forced switching policy against arguments of Canadian gastroenterologists not to switch IBD patients... Tyler Shandro 🕗 @shandro - Dec 12, 2019

David, a decade of experience in Europe, with 90 studies on switching to biosimilars that tell us switching is safe. That's why BC NDP Minister @adriandix agrees. And Crohn's & Colitis UK. And Dr. D'Haens of European Crohn's and Colitis Org. crohnsandcolitis.org.uk/news/newbiosl...

....

We welcome increased availability of effective treatment options for patients and understand the importance of the wise and careful use of NHS resources. Crohn's and Colitis UK has been working in the field of biosimilars to provide patient information and support since 2014 and is familiar with the evidence to date which reinforces the fact that biosimilars are as safe and effective as the reference products. The introduction of biosimilars for adalimumab brings potential opportunities for both patients and the NHS. However, it is vital that patients are fully informed about all the treatment options available to them and commissioners and health professionals adopt the principles of shared decision making. At a time when services are thinking about new contracts, we would also hope that patients' views are proactively sought and that things that matter to patients, including excipients, device and homecare packages, are given doe consideration.

Sarah Berry, Health Policy and Public Affairs Officer, Crohn's & Colitis UK


P David Shepherd 🕐 @DShepYEG - Dec 12, 2019

"We provided the Alberta gov't with an evidence-based counterargument against a non-medical switch for patients with IBD, fully supported by Canadian gastroenterologists and yet they still went ahead.

New Brunswick, April 2021

"This biosimilars initiative follows similar policies implemented by British Columbia and Alberta over the past 2 years, where tens of thousands of patients in each province were safely switched from an originator biologic drug to a biosimilar. Switching to biosimilars has also been conducted extensively in Europe, where countries have had over 15 years of experience with biosimilars."

"Biosimilars are just as safe and effective as the originator versions, as demonstrated by the experiences in British Columbia, Alberta and Europe."



The New Brunswick Department of Health has launched a Biosimilar versions. It follows the successful implementations of similar initiatives by British Columbia and Alberta. In addition, switching to biosimilars has been conducted extensively in Europe, where countries have had over 15 years of experience with biosimilars.

experience with biosimilars

The New Brunswick Department of Health has launched a Biosimilars Initiative which involves switching patients from originator biologic drugs to their biosimilar versions. It follows the successful implementations of similar initiatives by British Columbia and Alberta. In addition, switching to biosimilars has been conducted extensively in Europe, where countries have had over 15 years of

Overview

Information for Prescribers and Health Professional

What Are the Experiences of Patients in Europe, British Columbia, and Alberta?



We Don't Know- That's the Problem






Real-World Evidence of Safe Use (and Switching) Builds Confidence

Should Switching Studies Be Conducted Before Automatic Substitution? Canadian Survey, Oct. 2017

- The mere absence of negative data (i.e. problems) is not satisfactory to build confidence with physicians.
- <u>Switching data/studies that show</u> positive patient outcomes will do this.



The Forced-Substitution policies of some Canadian provinces more closely resemble the substitution policies of **Eastern Europe**....



ESTONIA: Permitted. Patient can refuse and pay price difference out-of-pocket.



LATVIA: Non bio-naïve patients can refuse and pay cost difference; the physician can prevent substitution. Others must use cheapest product.




POLAND: Permitted, pharmacists are to discuss with patient.



Surveys Have Shown Physicians Have <u>High Confidence in Biosimilars:</u> They Are Very Comfortable Prescribing Biosimilars to New Patients

Comfort Level Prescribing Biosimilars to a New Patient



Issues Arise With the Non-Medical Switching of Biologics

- Treatment plans are not "one size fits all."
- A patient often has to try several different medicines before finding the one which stabilizes their condition.
- Changing treatment may change the control a patient has over their condition.
- If a medicine is working for a patient, most doctors don't think it is a good idea to switch from one biologic to another for cost reasons only.



Canadian Physician Groups Opposed Non-Medical Switching

 Canadian Gastroenterologists issued statements opposing forced-switching policies enacted in Alberta and British Columbia.




Joint Statement From The Canadian Association Of Gastroenterology And Crohn's And Colitis Canada

The Canadian Association of Gastroenterology and Crohn's and Colitis Canada recently announced a joint statement that has been accepted for publication in the Journal of the Canadian Association of Gastroenterology. The paper, entitled Joint Canadian Association of Gastroenterology and Crohn's and Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease, was co-authored by esteemed Canadian gastroenterologists including: Drs Paul Moayyedi , Eric Benchimol , David Armstrong , and Grigorios I. Leontiadis .

Using the GRADE approach, authors reviewed evidence comparing biosimilars (available in Canada) to originator biologics for the treatment of patients with inflammatory bowel disease. They evaluated efficacy, safety, cost and acceptance by patients.

"Non-medical switching in patients being treated with a reference biologic is generally not accepted by learned societies and the consulted clinicians."

<u>"Safety of switching biologics and their interchangeability"</u>,
 INESS Report (Quebec), May 2020



Canadian Patient Groups Also Strongly Opposed These Policies



Patients, NDP call on province to reconsider upcoming change to not cover biologic drugs

MOIRA WYTON Updated: January 15, 2020



Arthritis patient Wilma Ritter speaks at the Federal Building on Wednesday, Jan. 15, 2020, in front of other Albertans with chronic illness who are devastated by the UCP government's decision to switch from biologic to biosimilar medications. ED KAISER / POSTMEDIA

8EI ′C	< Home	WS		
	EDMONTON News Members of Crohn's, co protest potential non-n policy			
IBD patients say they weren't consulted on forced switch to biosimilars				
Dec 16, 2019	'Back at square one:' B.C. Crohn's patient struggles with forced transition			

to biosimilar medication

More than 12,000 people in B.C. have switched to biosimilar medications since the province announced it would stop funding three drugs

GLENDA LUYMES Updated: February 9, 2020

Takeaways

- Canadian patients and physicians have strong concerns with forced-substitution policies. Survey data has borne these concerns out.
- Contrary to the assertions of forced-switching proponents, these policies represent a stark contrast with those of Western Europe.
- The European experience in particular shows that forced-substitution is not necessary to achieve high uptake and savings.
- Government policies incentivizing the use of one particular product distort the treatment-decision making process and may create pushback from physicians and patients.
- Expanding (rather than restricting) physician/patient choice reimbursing multiple products competing on a level playing field has contributed to the success of biosimilars in Europe.

For More Information, Read our GaBI Whitepapers:

"Policy Recommendations for a Sustainable Biosimilars Market: Lessons from Europe"

- Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
- GaBI Journal, Volume 9 / Year 2020 / Issue 2

"US Biosimilars Market on Pace With Europe"

- Madelaine Feldman, MD FACR; Michael S Reilly, Esq,
- GaBI Journal, Volume 9 / Year 2020 / Issue 4

"A Critical Review of Substitution Policy for Biosimilars in Canada"

- Michael S Reilly, Esq; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
- GaBI Journal, Volume 10 / Year 2021 / Issue 3

Available at www.gabi-journal.net



Continuous manufacturing versus botch manufacturing: benefits, opportunities and challenges for more